Comparative efficacy and safety of treatments for localised prostate cancer: An application of network meta-analysis

BMJ Open

Volumn 4, Issue 5, 2014, Pages

  Xiong, Tengbin ^a   Turner, Rebecca M ^b   Wei, Yinghui ^c,d   Neal, David E ^a   Lyratzopoulos, Georgios ^a   Higgins, Julian P T ^b,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d UNIVERSITY OF PLYMOUTH   (United Kingdom)

^e UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE TOXICITY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; COMPARATIVE EFFECTIVENESS; CRYOTHERAPY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL DISEASE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE; META ANALYSIS; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; UROGENITAL TRACT DISEASE; WATCHFUL WAITING; ADVERSE EFFECTS; COMPARATIVE STUDY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THERAPEUTICS; TREATMENT OUTCOME;

EID: 84901492219     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004285     Document Type: Article

References (103)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC CancerBase No.10. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr (accessed 8 Aug 2011).
3. Cancer Research UK. Prostate cancer - UK incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence/ (accessed 8 Aug, 2011).
4. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2008. Bethesda, MD: National Cancer Institute, 2011. http://seer.cancer. gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site.
5. National Cancer Institute. Prostate cancer. http://www.cancer.gov/ cancertopics/types/prostate (accessed 8 Aug 2011).
6. National Cancer Institute. Cancer advances in focus-prostate cancer. http://www.cancer.gov/cancertopics/factsheet/cancer-advances-in-focus/prostate (accessed 8 Aug 2011).
7. Lyratzopoulos G, Barbiere JM, Greenberg DC, et al. Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. BMJ 2010;340:c1928.
8. National Collaborating Centre for Cancer. NICE clinical guideline 58. Prostate cancer: diagnosis and treatment. Evidence review. London: National Institute for Health and Clinical Excellence, 2008.
9. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Accosication of Urology, 2012.
10. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. American Urological Association, 2011.
11. Andersson SO, Andren O, Lyth J, et al. Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol 2011;45:177-83.
12. Wilt TJ, Brawer MK, Barry MJ, et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009;30:81-7.
13. Donovan J, Mills N, Smith M, et al. Quality improvement report: improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. BMJ 2002;325:766-70.
14. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900. (Pubitemid 41502718)
15. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24. (Pubitemid 39334902)
16. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
17. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org.
18. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration 's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
19. Pilepich MV, Krall JM, Sause WT, et al . Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate - analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987;13:351-7. (Pubitemid 17053947)
20. Nielsen ME, Makarov DV, Humphreys E, et al. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "nadir + 2"? Urology 2008;72:389-93; discussion 394-385.
21. Smith TC, Spiegelhalter DJ, Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 1995;14:2685-99. (Pubitemid 26014258)
22. Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011. http://www.nicedsu.org.uk (accessed Apr 2012).
23. Lu G, Ades AE. Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 2006;101:447-59. (Pubitemid 43972289)
24. Lunn DJ, Thomas A, Best N, et al. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-37.
25. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane database of systematic reviews. Int J Epidemiol 2012;41:818-27.
26. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
27. Akakura K, Suzuki H, Ichikawa T, et al. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn J Clin Oncol 2006;36:789-93. (Pubitemid 47090734)
28. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84. (Pubitemid 40638368)
29. Chin JL, Ng CK, Touma NJ, et al. Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis 2008;11:40-5. (Pubitemid 351250328)
30. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005;92:488-98. (Pubitemid 40395529)
31. Dearnaley DP, Khoo VS, Norman AR, et al . Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72. (Pubitemid 29088118)
32. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007;8:475-87. (Pubitemid 46805903)
33. Dearnaley DP, Sydes MR, Langley RE, et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother Oncol 2007;83:31-41. (Pubitemid 46527948)
34. Donnelly B, Saliken J, Brasher P, et al. Randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. The American Urological Association Annual Meeting. Abstract 1141. 2007.
35. Graversen PH, Nielsen KT, Gasser TC, et al. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen-year follow-up. Urology 1990;36:493-8.
36. Koper PC, Jansen P, van Putten W, et al. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol 2004;73:1-9. (Pubitemid 39304119)
37. Koper PC, Stroom JC, van Putten WL, et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999;43:727-34. (Pubitemid 29152645)
38. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132-8.
39. Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982;128:502-4. (Pubitemid 12037692)
40. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006;24:1990-6. (Pubitemid 46622106)
41. Pollack A, Hanlon AL, Horwitz EM, et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 2006;64:518-26. (Pubitemid 43083441)
42. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105. (Pubitemid 34787842)
43. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6. (Pubitemid 34988337)
44. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635-42.
45. Tait DM, Nahum AE, Meyer LC, et al. Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol 1997;42:121-36. (Pubitemid 27132741)
46. Yeoh EE, Fraser RJ, McGowan RE, et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2003;55:943-55. (Pubitemid 36286996)
47. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:980-8.
48. Al-Mamgani A, van Putten WL, van der Wielen GJ, et al. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys 2011;79:1004-12.
49. Arcangeli G, Fowler J, Gomellini S, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:1013-21.
50. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2010;78:11-18.
51. Beckendorf V, Guerif S, Le Prise E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056-63.
52. Beckendorf V, Guerif S, Le Prise E, et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004;60:1056-65. (Pubitemid 39440789)
53. Bill-Axelson A, Holmberg L, Filen F, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008;100:1144-54.
54. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708-17.
55. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13:43-54.
56. Donnelly BJ, Saliken JC, Brasher PM, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010;116:323-30.
57. Giberti C, Chiono L, Gallo F, et al. Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 2009;27:607-12.
58. Heemsbergen WD, Hoogeman MS, Witte MG, et al. Increased risk of biochemical and clinical failure for prostate patients with a large rectum at radiotherapy planning: results from the Dutch trial of 68 GY versus 78 Gy. Int J Radiat Oncol Biol Phys 2007;67:1418-24. (Pubitemid 46467163)
59. Johansson E, Bill-Axelson A, Holmberg L, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 2009;55:422-30.
60. Johansson E, Steineck G, Holmberg L, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011;12:891-9.
61. Kuban DA, Levy LB, Cheung MR, et al . Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 2011;79:1310-17.
62. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:67-74. (Pubitemid 350251041)
63. Marzi S, Saracino B, Petrongari MG, et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res 2009;28:117.
64. Norkus D, Miller A, Kurtinaitis J, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlenther Onkol 2009;185:715-21.
65. Norkus D, Miller A, Plieskiene A, et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response. Medicina (Kaunas) 2009;45:469-75.
66. Peeters ST, Heemsbergen WD, van Putten WL, et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005;61:1019-34. (Pubitemid 40340897)
67. Peeters ST, Lebesque JV, Heemsbergen WD, et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006;64:1151-61.
68. Robinson JW, Donnelly BJ, Siever JE, et al. A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer: quality of life outcomes. Cancer 2009;115:4695-704.
69. Syndikus I, Morgan RC, Sydes MR, et al. Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397). Int J Radiat Oncol Biol Phys 2010;77:773-83.
70. van der Wielen GJ, Hoogeman MS, Dohle GR, et al. Dose-volume parameters of the corpora cavernosa do not correlate with erectile dysfunction after external beam radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2008;71:795-800.
71. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203-13.
72. Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 2011;81:1271-8.
73. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2006;66:1072-83. (Pubitemid 44633501)
74. Yeoh EK, Holloway RH, Fraser RJ, et al. Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2009;73:46-52.
75. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010;28:1106-11.
76. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. (Pubitemid 41352111)
77. Widmark A. Prospective Randomized Trial Comparing External Beam Radiotherapy versus Watchful Waiting in Early Prostate Cancer (T1b-T2, pN0, Grade 1-2, M0). 2011 annual meeting of the American Society for Therapeutic Radiology and Oncology, ASTRO 2011. http://www.oncolink.org/conferences/article. cfm?id=2171&ss=350
78. Fransson P, Damber JE, Tomic R, et al. Quality of life and symptoms in a randomized trial of radiotherapy versus deferred treatment of localized prostate carcinoma. Cancer 2001;92:3111-19. (Pubitemid 33136207)
79. Fransson P, Damber JE, Widmark A. Health-related quality of life 10 years after external beam radiotherapy or watchful waiting in patients with localized prostate cancer. Scand J Urol Nephrol 2009;43:119-26.
80. Bannuru RR, Dvorak T, Obadan N, et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann Intern Med 2011;155:171-8.
81. Hegarty J, Beirne PV, Walsh E, et al. Radical prostatectomy versus watchful waiting for prostate cancer. Cochrane Database Syst Rev 2010;11:CD006590.
82. Hummel S, Simpson EL, Hemingway P, et al. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-108, iii-iv.
83. Koukourakis G, Kelekis N, Armonis V, et al. Brachytherapy for prostate cancer: a systematic review. Adv Urol 2009:327945.
84. Morris DE, Emami B, Mauch PM, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys 2005;62:3-19. (Pubitemid 40591918)
85. Olsen DR, Bruland OS, Frykholm G, et al. Proton therapy-a systematic review of clinical effectiveness. Radiother Oncol 2007;83:123-32. (Pubitemid 46776914)
86. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys 2008;72:972-9.
87. Peinemann F, Grouven U, Bartel C, et al . Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 2011;60:881-93.
88. Peinemann F, Grouven U, Hemkens LG, et al. Low-dose rate brachytherapy for men with localized prostate cancer. Cochrane Database Syst Rev 2011;7:CD008871.
89. Pieters BR, de Back DZ, Koning CC, et al. Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review. Radiother Oncol 2009;93:168-73.
90. Shelley M, Wilt TJ, Coles B, et al. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev 2007;3:CD005010.
91. Staffurth J. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol) 2010;22:643-57.
92. van Tol-Geerdink JJ, Stalmeier PF, Pasker-de Jong PC, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006;64:534-43. (Pubitemid 43083443)
93. Viani GA, da Silva LG, Stefano EJ. High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2012;83:e619-25.
94. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 2009;74:1405-18.
95. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435-48. (Pubitemid 351665443)
96. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013;368:436-45.
97. Lu G, Ades A. Modeling between-trial variance structure in mixed treatment comparisons. Biostatistics 2009;10:792-805.
98. Sajid S, Kotwal AA, DaleW. Interventions to improve decision making and reduce racial and ethnic disparities in the management of prostate cancer: a systematic review. J Gen Intern Med 2012;27:1068-78.
99. Abdollah F, Schmitges J, Sun M, et al. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol 2012;19:836-44; author reply 844-835.
100. Boorjian SA, Karnes RJ, Viterbo R, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011;117:2883-91.
101. Cooperberg MR, Vickers AJ, Broering JM, et al. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010;116:5226-34.
102. Sooriakumaran P, Nyberg T, Akre O, et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 2014;348:g1502.
103. Zelefsky MJ, Eastham JA, Cronin AM, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010;28:1508-13.